Medtronic pacing feature delays progression of AF

|About: Medtronic plc (MDT)|By:, SA News Editor

Results from Medtronic's (MDT +1.2%) MINERVA clinical study show that its ATP algorithm reduces the development of persistent atrial fibrillation by 58% compared to standard pacemakers. The algorithm restores the heart back to its normal rhythm by pacing during abnormally fast atrial rhythms. In the study, it played a significant role in slowing the progression of the disease by successfully terminating atrial tachycardia/atrial fibrillation episodes.

The company believes that the reduction in these episodes could save $1,218 in healthcare costs per patient over a 10-year time frame.